Alessandra Iurlo
A5006810419- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Acute Myeloid Leukemia Research
- Kruppel-like factors research
- Acute Lymphoblastic Leukemia research
- HER2/EGFR in Cancer Research
- Hemoglobinopathies and Related Disorders
- Platelet Disorders and Treatments
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- PI3K/AKT/mTOR signaling in cancer
- Erythrocyte Function and Pathophysiology
- Protein Degradation and Inhibitors
- Chemotherapy-induced cardiotoxicity and mitigation
- Mast cells and histamine
- Synthesis of Tetrazole Derivatives
- Fungal Plant Pathogen Control
- Quinazolinone synthesis and applications
- Click Chemistry and Applications
- Renal Diseases and Glomerulopathies
- Biochemical and Molecular Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Ospedale Maggiore
2016-2025
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2009-2024
Politecnico di Milano
2024
University of Milan
2014-2023
IRCCS Policlinico San Donato
2023
University of Amsterdam
2018
Amsterdam UMC Location University of Amsterdam
2018
Gruppo Italiano per il Trapianto di Midollo Osseo
2012
Mylan (Switzerland)
2008
Current treatment recommendations for patients with polycythemia vera call maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in randomized clinical trial.We randomly assigned 365 adults JAK2-positive who were being treated phlebotomy, hydroxyurea, or both to receive either more intensive (target hematocrit, <45%) (low-hematocrit group) 45 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular...
Imatinib is effective for the treatment of chronic myeloid leukemia (CML). However even undetectable BCR‐ABL1 by Q‐RT‐PCR does not equate to eradication disease. Digital‐PCR (dPCR), able detect 1 positive cell out 10 7 , has been recently developed. The ISAV study a multicentre trial aimed at validating dPCR predict relapses after imatinib discontinuation in CML patients with Q‐RT‐PCR. under therapy since more than 2 years and PCR least 18 months were eligible. Patients monitored standard 36...
Abstract Ruxolitinib (RUX) is extensively used in myelofibrosis (MF). Despite its early efficacy, most patients lose response over time and, after discontinuation, have a worse overall survival (OS). Currently, criteria able to predict OS RUX-treated are lacking, leading uncertainty regarding the switch second-line treatments. In this study, we investigated predictors of collected 6 months RUX 209 MF participating real-world ambispective observational RUXOREL-MF study (NCT03959371)....
Congenital dyserythropoietic anemia type II (CDAII) is an autosomal recessive disease characterized by ineffective erythropoiesis, hemolysis, erythroblast morphological abnormalities, and hypoglycosylation of some red blood cell (RBC) membrane proteins. Recent studies indicated that CDAII caused a defect disturbing Golgi processing in erythroblasts. A linkage analysis located candidate region on chromosome 20, termed the CDAN2 locus, majority patients but aberrant gene has not so far been...
Background After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before receipt ruxolitinib may predict drug discontinuation in and reasons for discontinuation, phase at salvage therapies influence outcome. Methods A centralized electronic clinical database was created 20 European hematology centers, including laboratory data 524 who received myelofibrosis. Results At 3 years, 40.8% had...
Chronic Myeloid Leukemia (CML) patients in sustained "deep molecular response" (DMR) may stop TKI treatment without disease recurrence; however, half of them lose response shortly after withdrawing. Well-defined eligibility criteria to predict a safe discontinuation up-front are still missing. Relapse is probably due residual quiescent resistant leukemic stem cells (LSCs) supposedly transcriptionally low/silent and not easily detectable by BCR-ABL1 qRT-PCR. Bone marrow Ph+CML CD34+/CD38-LSCs...
Abstract We retrospectively studied 181 patients with polycythaemia vera ( n =67), essential thrombocythaemia =67) or primary myelofibrosis =47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd–Chiari syndrome (BCS) and portal were diagnosed in 31 (17.1%) 109 (60.3%) patients, respectively; isolated the mesenteric splenic veins was detected 18 23 cases, respectively. After this index event, followed for 735 patient years (pt-years) experienced recurrences...
Abstract Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival CML patients has become very close to normal. The next, ambitious, step is bring as many possible into a condition treatment-free remission (TFR). Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA; Italian Group for Hematologic Diseases Adult) Working Party (WP) developed project aimed at...
We report the clinical presentation and risk factors for survival in 175 patients with myeloproliferative neoplasms (MPN) COVID-19, diagnosed between February June 2020. After a median follow-up of 50 days, mortality was higher than general population reached 48% myelofibrosis (MF). Univariate analysis, showed significant relationship death age, male gender, decreased lymphocyte counts, need respiratory support, comorbidities diagnosis MF, while no association essential thrombocythemia (ET),...
BackgroundWhether phlebotomy alone can adequately maintain target hematocrit in patients with low-risk polycythemia vera (PV) remains elusive.MethodsIn a phase 2 open-label randomized trial, we compared ropeginterferon alfa-2b (ropeg; 100 μg every weeks) only regarding maintenance of median level (≤45%) over 12 months the absence progressive disease (primary end point). In follow-up, crossover to alternative treatment group was allowed if primary point not met.ResultsIn total, 127 were...
Abstract Background Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared patients the myeloproliferative phenotype. Aims Methods Prognostic correlates of phenotype were explored in 886 ruxolitinib‐treated primary/secondary MF (PMF/SMF) included RUX‐MF retrospective study. Cytopenia was defined as: leukocyte count <4 × 10 9 /L and/or hemoglobin <11/<10 g/dL (males/females) platelets <100 /L. Results Overall, 407 (45.9%) had...
Abstract Mechanisms through which mature megakaryocytes (Mks) and their progenitors sense the bone marrow extracellular matrix to promote lineage differentiation in health disease are still partially understood. We found PIEZO1, a mechanosensitive cation channel, be expressed mouse human Mks. Human mutations PIEZO1 have been described associated with blood cell disorders. Yet, role for megakaryopoiesis proplatelet formation has never investigated. Here, we show that activation of increases...
Cutaneous manifestations of hematologic malignancy represent both a clinical challenge for the treating physician and pathophysiological model advancing knowledge on individual neoplasms. Indeed, growing body evidence supports concept recurrent molecular defects associating with specific features, as best exemplified by VEXAS. Herein neutrophilic eosinophilic dermatoses potential interest hematologists dermatologists will be reviewed, including subcorneal pustular dermatosis-type IgA...
Optimal adherence to imatinib therapy is of paramount importance maximise treatment effectiveness in patients with chronic myeloid leukaemia (CML). The main objective this study was investigate patient-reported personal factors associated behaviour.Analysis conducted on 413 CML receiving long-term imatinib. Adherence behaviour measured the Morisky Medication Scale and investigated included: quality life, perceived social support, fatigue, symptom burden, psychological wellbeing desire for...